Want to see QNRX full AI Analyst Report?

Quoin Pharmaceuticals (QNRX) Price & Analysis

383 Followers

QNRX Stock Chart & Stats

$11.72

-$0.04(-5.59%)

At close: Jan 08 4:00 PM EST

$11.72

-$0.04(-5.59%)

Day’s Range― - ―

52-Week Range$3.25 - $41.80

Previous CloseN/A

Volume155.80K

Average Volume (3M)629.04K

Market Cap

$8.98M

Enterprise Value$6.15M

Total Cash (Recent Filing)$3.12M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta-0.87

Next Earnings

Aug 06, 2026

EPS Estimate

-1.61

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-17.68

Shares Outstanding2,008,418

10 Day Avg. Volume1,633,105

30 Day Avg. Volume629,040

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.65

Price to Sales (P/S)0.00

P/FCF Ratio-1.60

Enterprise Value/Market Cap0.68

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-246.78

Enterprise Value/Ebitda-0.36

Forecast

1Y Price Target

$23.25

Price Target Upside98.38% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-6.48

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

FDA Acceptance Of Brand NameConditional FDA acceptance of the QYLEKI brand and the stated plan to start a pivotal Phase 3 in 2H 2026 (targeting a 2027 NDA) materially reduces regulatory uncertainty and clarifies a realistic pathway to first-in-disease commercialization for Netherton Syndrome.

Global Orphan/fast-track DesignationsMultiple orphan and expedited designations across the U.S., EU and Japan provide regulatory incentives, prioritized review and potential market exclusivity, strengthening commercial economics and making global launch and reimbursement strategies more viable long term.

Debt-free Balance SheetA lack of debt lowers financial distress risk and preserves strategic optionality, allowing the company to prioritize R&D and pivotal trial execution without near-term fixed interest obligations, which is materially supportive during the pre-commercial development phase.

Bears Say

No Revenue & Persistent LossesThe company remains pre-commercial with no revenue and recurring operating and net losses; absent product approval or external funding, continued losses will deplete resources and constrain the firm’s ability to self-fund pivotal trials and early commercialization efforts over the next 2–6 months.

Material Negative Operating Cash FlowSustained negative operating and free cash flow of roughly -$15.9M TTM indicates material cash burn; this undermines runway and makes the company dependent on external financing, potentially diluting shareholders and diverting management focus from development execution.

Eroding Equity & Limited AssetsDeclining shareholder equity and a modest asset base (~$15.7M TTM) reduce financial flexibility to absorb trial costs or commercial launch investments; this raises the likelihood of near-term capital raises and associated dilution if trial timelines or costs extend.

Quoin Pharmaceuticals News

Quoin Pharmaceuticals receives notice of allowance for QRX003 patent

Quoin Pharmaceuticals (QNRX) announced that the United States Patent and Trademark Office, or USPTO, has issued a notice...

5d ago

QNRX

Quoin Pharmaceuticals announces conditional FDA approval for Qyleki brand name

Quoin Pharmaceuticals (QNRX) announced that the FDA has conditionally approved Qyleki as the proposed brand name for QRX003,...

12d ago

QNRX

Quoin Pharmaceuticals completes establishment of subsidiary in Japan

Quoin Pharmaceuticals (QNRX) announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part...

17d ago

QNRX

Quoin reports positive pediatric data in Netherton Syndrome program

Quoin Pharmaceuticals (QNRX) announced a positive clinical update from its ongoing pediatric Netherton Syndrome Compassionate Use program evaluating...

19d ago

QNRX

Quoin Pharmaceuticals initiated with a Buy at ThinkEquity

ThinkEquity initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $12 price target Quoin is a...

20d ago

QNRX

Naz Rahman Maintains Buy on Quoin as QYLEKI Progress Offsets Financing Risks, While Cutting 12-Month Price Target from $40 to $16

Quoin Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahman from...

10d ago

QNRX

Quoin Advances QYLEKI Toward First Netherton Therapy

Quoin Pharmaceuticals ( ($QNRX) ) has issued an update. On June 23, 2026, Quoin Pharmaceuticals said the U.S....

12d ago

QNRX

Quoin Wins Japan Orphan Drug Status for QRX003

Quoin Pharmaceuticals ( ($QNRX) ) has shared an announcement. On March 11, 2026, Quoin Pharmaceuticals announced that Japan’s...

1M ago

QNRX

Quoin Pharmaceuticals granted Orphan Drug Designation for QRX003 in Japan

Quoin Pharmaceuticals (QNRX) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted Orphan Drug...

1M ago

QNRX

Quoin Pharmaceuticals submits QRX003 IND application to FDA

Quoin Pharmaceuticals (QNRX) announced the submission of an investigational new drug, or IND, application to the FDA for...

1M ago

QNRX

Quoin Pharmaceuticals initiated with a Buy at Lucid Capital

Lucid Capital initiated coverage of Quoin Pharmaceuticals (QNRX) with a Buy rating and $30 price target Quoin is...

2M ago

QNRX

Quoin Pharmaceuticals provides regulatory update on QRX009 topical rapamycin

Quoin Pharmaceuticals (QNRX) provided a clinical and regulatory update for its QRX009 topical rapamycin development programs. The company...

2M ago

QNRX

Quoin’s QRX003 Trial Moves Forward In Rare Skin Disease, Keeping QNRX On Investor Watch

Quoin Pharmaceuticals Ltd ($QNRX) announced an update on their ongoing clinical study. The multicenter study “A Multicenter, Open-label...

3M ago

QNRX

Financing Covenants Put Quoin Pharmaceuticals at Heightened Risk of Funding Shortfall and Program Delays

Quoin Pharmaceuticals Ltd (QNRX) has disclosed a new risk, in the Debt & Financing category. Quoin Pharmaceuticals Ltd....

3M ago

QNRX

QNRX FAQ

What was Quoin Pharmaceuticals’s price range in the past 12 months?

Quoin Pharmaceuticals lowest stock price was $3.25 and its highest was $41.80 in the past 12 months.

What is Quoin Pharmaceuticals’s market cap?

Quoin Pharmaceuticals’s market cap is $8.98M.

When is Quoin Pharmaceuticals’s upcoming earnings report date?

Quoin Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 32 days.

How were Quoin Pharmaceuticals’s earnings last quarter?

Quoin Pharmaceuticals released its earnings results on May 07, 2026. The company reported -$1.77 earnings per share for the quarter, beating the consensus estimate of -$2.17 by $0.4.

Is Quoin Pharmaceuticals overvalued?

According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Quoin Pharmaceuticals pay dividends?

Quoin Pharmaceuticals does not currently pay dividends.

What is Quoin Pharmaceuticals’s EPS estimate?

Quoin Pharmaceuticals’s EPS estimate is -1.61.

How many shares outstanding does Quoin Pharmaceuticals have?

Quoin Pharmaceuticals has 2,008,418 shares outstanding.

What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?

Quoin Pharmaceuticals reported an EPS of -$1.77 in its last earnings report, beating expectations of -$2.17. Following the earnings report the stock price went down -0.933%.

Which hedge fund is a major shareholder of Quoin Pharmaceuticals?

Currently, no hedge funds are holding shares in QNRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Quoin Pharmaceuticals

Quoin Pharmaceuticals, Ltd. operates as a specialized pharmaceutical firm, concentrating its efforts on devising therapeutic solutions for rare and orphan medical conditions. Its flagship offering, QRX003, is a topical lotion specifically formulated to address Netherton Syndrome. Furthermore, the company is advancing QRX004 for the management of dystrophic epidermolysis bullosa, alongside QRX006, a prospective therapy for an additional rare dermatological ailment. The organization maintains its operational base in Ashburn, Virginia.

Quoin Pharmaceuticals (QNRX) Earnings & Revenues

Historic Earnings Reports

QNRX Stock 12 Month Forecast

Average Price Target

$23.25

▲(98.38% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","36":"$36","11.25":"$11.25","19.5":"$19.5","27.75":"$27.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$23.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,11.25,19.5,27.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,7.04,9.370000000000001,11.7,14.030000000000001,16.36,18.69,21.020000000000003,23.35,25.68,28.01,30.340000000000003,32.67,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,6.136153846153846,7.562307692307693,8.98846153846154,10.414615384615384,11.84076923076923,13.266923076923078,14.693076923076923,16.119230769230768,17.545384615384616,18.97153846153846,20.397692307692306,21.823846153846155,{"y":23.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.71,5.270769230769231,5.831538461538462,6.392307692307693,6.953076923076923,7.5138461538461545,8.074615384615385,8.635384615384616,9.196153846153846,9.756923076923076,10.317692307692308,10.87846153846154,11.439230769230768,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.225,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.82,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.36,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.52,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.21,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.77,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.71,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >